


IASLC



# 2022 Targeted Therapies of Lung Cancer Meeting

FEBRUARY 22-26, 2022 | WORLDWIDE VIRTUAL EVENT

# PROGRAM

#TTLC22

# IASLC TTLC 2022 Program

## Table of Contents

### Program

---

<b>Day 1   Tuesday, February 22, 2022</b>	<b>5</b>
---	----------

<b>Day 2   Wednesday, February 23, 2022</b>	<b>7</b>
---	----------

<b>Day 3   Thursday, February 24, 2022</b>	<b>10</b>
--	-----------

<b>Day 4   Friday, February 25, 2022</b>	<b>12</b>
--	-----------

<b>Day 5   Saturday, February 26, 2022</b>	<b>17</b>
--	-----------

### Posters

---

<b>Posters</b>	<b>19</b>
----------------	-----------

# Day 1 Tuesday, February 22, 2022

## 14:00 - 15:30 Session 1: Targeted Therapies - EGFR

---

Session Chairs: Lyudmila Bazhenova, USA & Natasha Leighl, Canada

- 14:00**    **Approved and Experimental Therapies for Exon 20 Insertion EGFR Mutations**  
*Zofia Piotrowska, USA*
- 14:10**    **Open Questions Around First-line Treatment for EGFR Mutant Lung Cancers**  
*Helena Yu, USA*
- 14:20**    **Acquired Resistance to EGFR TKIs**  
*Katerina Politi, USA*
- 14:30**    **Updates on Brain Metastases and Leptomeningeal Disease in EGFR + NSCLC**  
*Sarah Goldberg, USA*
- 14:40**    **Lineage Plasticity**  
*Ryan Gentzler, USA*
- 14:50**    **What is the Current and Future Role of IO in EGFR and Other Driver Mutation-positive NSCLC?**  
*Jonathan Riess, USA*
- 15:00**    **Live Panel Discussion**  
*Julia Rotow, USA*  
*Balazs Halmos, USA*  
*Hatim Husain, USA*  
*Mary Jo Fidler, USA*  
*Adam Schoenfeld, USA*  
*Brian Henick, USA*

## 15:30 - 16:15 Keynote Session

---

Session Chairs: Lecia Sequist, USA & Paul A. Bunn, Jr., USA

- 15:30**    **The Journey to Curing Advanced Lung Cancer**  
*Karen Kelly, USA*
- 16:00**    **Live Discussion**

**16:30 - 18:00      Session 2: Targeted Therapies - ALK & ROS1 Inhibitors**

---

Session Chairs: Stephen Liu, USA & Natalie Vokes, USA

- 16:30      What is the Optimal 1st Line ALK Therapy in 2022?**  
*Shirish Gadgeel, USA*
- 16:40      Acquired Resistance to ALK Inhibitors**  
*Sai-Hong Ignatius Ou, USA*
- 16:50      Emerging ALK Inhibitors and Combinations**  
*Jessica Lin, USA*
- 17:00      Acquired Resistance to ROS1 Inhibitors**  
*Christine Lovly, USA*
- 17:10      Emerging ROS1 Inhibitors and Combinations**  
*Alexander Drilon, USA*
- 17:20      Brain Mets and Leptomeningeal Disease in ALK and ROS1 NSCLC**  
*Joel Neal, USA*
- 17:30      Live Panel Discussion**  
*Joshua Sabari, USA*  
*Dara Aisner, USA*  
*Joshua Reuss, USA*  
*Jose Pacheco, USA*  
*Matthew Gubens, USA*  
*Nagla Abdel Karim, USA*

**18:05 – 19:05      Satellite CME Symposium: Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies Presented by PeerView**

---

# Day 2 Wednesday, February 23, 2022

**14:00 - 15:40****Session 3: Immunotherapy - IO and other Novel Combinations**

---

Session Chairs: Karen Reckamp, USA &amp; Lova Sun, USA

- 14:00 Immunotherapy Combinations Beyond CTLA-4**  
*Vamsidhar Velcheti, USA*
- 14:10 Immunotherapy Combination with Small Molecule Inhibitors**  
*Liza Villaruz, USA*
- 14:20 Immunomodulation with Anti-angiogenesis Inhibitors**  
*Scott Gettinger, USA*
- 14:30 IO Targeting Adenosine Pathway and NK Cells**  
*Melissa Johnson, USA*
- 14:40 Co-stimulatory Molecules**  
*Prasad Adusumilli, USA*
- 14:50 Personalized Immunotherapy**  
*Jyoti Patel, USA*
- 15:00 Lung Cancer Risk Reduction with IO Agents**  
*Eva Szabo, USA*
- 15:05 Live Panel Discussion**  
*Jack West, USA*  
*Deborah Doroshov, USA*  
*Hossein Borghaei, USA*  
*Erin Schenk, USA*  
*Daniel Morgensztern, USA*  
*Rachel Sanborn, USA*

**15:45 - 16:55****Best Fellows Oral Abstract Session**

---

Session Chairs: Kathryn Mileham, USA & Rogerio Lilenbaum, USA

- 15:45**    **Dissecting the Clinicopathologic, Genomic, and Immunophenotypic Correlates of KRAS G12D Mutated Non-small Cell Lung Cancer**  
*Biagio Ricciuti, USA*
- 15:55**    **Genomic and Immune Characteristics of BRAF Mutated Non-small Cell Lung Cancer**  
*Fares Alsawah, USA*
- 16:05**    **Investigating the Efficacy of Osimertinib in Patients with Tumors Harboring the Uncommon EGFR Exon 19 Deletion, L747\_A750delinsP**  
*Michael Grant, USA*
- 16:15**    **Antitumor Activity of KIN-2787, a Next-Generation pan-RAF Inhibitor, in Preclinical Models of Human BRAF-alteration Driven Non-small Cell Lung Cancer (NSCLC)**  
*Tadashi Manabe, USA*
- 16:25**    **Low Dose CT (LDCT) Screening is as Efficacious in Asian Female Never-Smokers as in Asian Male Ever-Smokers in Detecting Lung Cancer: A Systemic Review and Meta-analysis of Lung Cancer Studies**  
*Shannon Zhang, USA*
- 16:35**    **Live Discussion**

**17:00 - 18:25****Session 4: Targeted Therapies - All the Others**

---

Session Chairs: Amy Cummings, USA &amp; Thomas Stinchcombe, USA

- 17:00 Inhibition of BRAF**  
*Bruce Johnson, USA*
- 17:10 HER2 in Lung Cancers - Knowledge Grows Opportunities Awaits**  
*Mark Kris, USA*
- 17:20 Anti-MET Targeted Therapies**  
*Xiuning Le, USA*
- 17:30 RET Fusions**  
*Justin Gainor, USA*
- 17:40 NTRK Inhibitors**  
*Karen Kelly, USA*
- 17:45 Using Pulsed and Low Dose XRT to address PD1 Resistance**  
*James Welsh, USA*
- 17:50 NRG1 Fusions**  
*Parneet Cheema, Canada*
- 17:55 Live Panel Discussion**  
*Ravi Salgia, USA*  
*Paul Paik, USA*  
*Aaron Lisberg, USA*  
*Helen Ross, USA*  
*Wade Jams, USA*

# Day 3 Thursday, February 24, 2022

## 14:00 - 15:40 Session 5: Immunotherapy - Practical Considerations

---

Session Chairs: Jia Luo, USA & Sandip Patel, USA

- 14:00 PDL1 & TMB**  
*Fred R. Hirsch, USA*
- 14:10 Liquid Biopsies for Monitoring Immunotherapy Response**  
*Valsamo Anagnostou, USA*
- 14:20 Immunotherapy - Practical Considerations - Clinical Trial Considerations**  
*Mary Redman, USA*
- 14:30 Duration of Immunotherapy: How Much, How Long?**  
*Marina Garassino, USA*
- 14:40 Practical Considerations Regarding Use of Immunotherapy in the Clinic**  
*Julie Brahmer, USA*
- 14:50 Impact of Co-occurring Mutations**  
*Ferdinandos Skoulidis, USA*
- 15:00 Blood Based Biomarkers for Immunotherapy**  
*Charu Aggarwal, USA*
- 15:10 Live Panel Discussion**  
*Elaine Shum, USA*  
*Jianjun Zhang, USA*  
*Rajwanth Veluswamy, USA*  
*Kai He, USA*  
*Kurt Schalper, USA*  
*David Rimm, USA*



**15:45 - 16:25 Faculty Keynote**

---

Session Chairs: Suresh Ramalingam, USA & Charu Aggarwal, USA

- 15:45**    **22 Years of Progress in the Treatment of Non-Small Cell Lung Cancer: Targeted Therapy, Immunotherapy and the IASLC Santa Monica Meeting**  
*Roy Herbst, USA*
- 16:15**    **Live Discussion**

**16:30 - 18:15 Session 6: Therapy for Early Stage**

---

Session Chairs: Jay Lee, USA & Jessica Donington, USA

- 16:30**    **Neoadjuvant IO**  
*Tina Cascone, USA*
- 16:40**    **Neoadjuvant IO+Chemo**  
*Patrick Forde, USA*
- 16:50**    **Neoadjuvant TKI Therapy**  
*Collin Blakely, USA*
- 17:00**    **Adjuvant IO + CT**  
*Heather Wakelee, USA*
- 17:10**    **Adjuvant Targeted Therapies**  
*Jonathan Goldman, USA*
- 17:20**    **Pros and Cons of Adjuvant vs Neoadjuvant**  
*David Carbone, USA*
- 17:30**    **MRD and Adjuvant Therapy**  
*Max Diehn, USA*
- 17:40**    **Circulating Tumor DNA for Early Detection**  
*Christian Rolfo, USA*
- 17:45**    **Live Panel Discussion**  
*Vincent Lam, USA*  
*Angel Qin, USA*  
*Edgardo Santos, USA*  
*Raymond Osarogiagbon, USA*  
*Sanja Dacic, USA*  
*Nasser Altorki, USA*

# Day 4 Friday, February 25, 2022

## 10:00 – 11:30 Session 7: Locally Advanced NSCLC

---

Session Chairs: Corey Langer, USA & Frances A Shepherd, Canada

- 10:00 Innovations in Radiotherapy for Lung Cancer**  
*Jeffrey Bradley, USA*
- 10:10 Immunotherapy in the Setting of SBRT**  
*Kristin Higgins, USA*
- 10:20 Consolidation Checkpoint Inhibition After Chemo-RT PD-1, PD-1 + CTLA4 Combination**  
*Jhanelle Gray, USA*
- 10:30 Concurrent Checkpoint Inhibition With Chemo-RT: Early Results and Ongoing Trials**  
*Nathan Pennell, USA*
- 10:40 Emerging Combination Immunotherapy Approaches in Locally Advanced NSCLC Combination of PD-1 Plus Other Novel Approaches**  
*Christine Bestvina, USA*
- 10:50 Role of Targeted Therapy Following Chemo-RT EGFR, PARP, Other Targeted Agents**  
*Gregory Durm, USA*
- 11:00 Live Panel Discussion**  
*David Kozono, USA*  
*Aparna Hegde, USA*  
*David Harpole, USA*  
*Jeffrey Crawford, USA*  
*J. Jack Lee, USA*  
*Jeff Petty, USA*

**11:45 - 13:15****Session 8: Mesothelioma/Thymic Carcinoma**

---

Session Chairs: Hedy Kindler, USA & Brendon Stiles, USA

- 11:45 Mesothelioma: Best Surgical Therapy with Neoadjuvant or Adjuvant Rx**  
*Harvey Pass, USA*
- 11:55 Mesothelioma and Thymic Carcinoma: RT Options and Timing**  
*Charles Simone, USA*
- 12:00 IO Neoadjuvant, Adjuvant, or Recurrent Rx: Mesothelioma/Thymic Carcinoma**  
*Edward Garon, USA*
- 12:10 Mesothelioma IO/CT Neoadjuvant, Adjuvant, or Recurrent**  
*Anne Tsao, USA*
- 12:20 Mesothelin as a Target**  
*Aaron Mansfield, USA*
- 12:30 Mesothelioma: Novel Targets**  
*Ibiayi Dagogo-Jack, USA*
- 12:40 Novel Therapies for Thymic Carcinomas**  
*Giuseppe Giaccone, USA*
- 12:45 Live Panel Discussion**  
*Antoinette Wozniak, USA*  
*John Wrangle, USA*  
*Marjorie Zauderer, USA*  
*Raffit Hassan, USA*  
*Erin Gillaspie, USA*  
*Kaushal Parikh, USA*

**13:30 - 15:00      Session 9: Antibody Drug Conjugates**

---

Session Chairs: Alex Adjei, USA & Victoria Lai, USA

- 13:30      Antibody Drug Conjugates to HER2 and HER3**  
*Pasi Jänne, USA*
- 13:40      ADCs to PTK7, AXL, ROR**  
*Hossein Borghaei, USA*
- 13:50      Antibody-drug Conjugates Directed Against Trop-2**  
*Ross Camidge, USA*
- 14:00      ADCs to CEACAM**  
*Benjamin Levy, USA*
- 14:10      Antibody Drug Conjugates to MET**  
*Tejas Patil, USA*
- 14:20      Other ADC Targets**  
*Grace Dy, USA*
- 14:30      Live Panel Discussion**  
*George Blumenschein, USA*  
*Afshin Dowlati, USA*  
*Hirva Mamdani, USA*  
*Saiama Waqar, USA*  
*Conor Steuer, USA*  
*Timothy Yap, USA*

**15:05 - 16:30 Early Career Workshop**

---

**Session Chairs:** Rosalyn Juergens, Canada & Shakun Malik, USA

- 15:05 Comparing and Contrasting Academia and Industry**  
*Leora Horn, USA*
- 15:10 Career Opportunities at FDA**  
*Erica Nakajima, USA*
- 15:15 Forging Your Own Paradigm**  
*Narjust Duma, USA*
- 15:20 The Changing Face of Community Oncology**  
*David Spiegel, USA*
- 15:25 Career Transitions – How the Academic Focus Can Change Over the Years**  
*Joan Schiller, USA*
- 15:30 Academic Leadership Roles**  
*John Heymach, USA*
- 15:35 Keeping Your Work Focused on Patients**  
*Ivy Elkins, USA*
- 15:40 Live Panel Discussion**  
*Jill Feldman, USA*  
*Kim Norris, USA*  
*Steven Dubinett, USA*  
*Peter Ujhazy, USA*  
*McGarry Houghton, USA*  
*Chandra Belani, USA*  
*Puneeth Iyengar, USA*  
*Jonathan Spicer, Canada*
- 16:10 Breakout Room Discussions**  
**Choosing a Career Path:** John Heymach, Puneeth Iyengar, David Spiegel, Leora Horn  
**Grant Writing/Submission:** Steven Dubinett, Kim Norris, Peter Ujhazy, McGarry Houghton  
**Policy/Advocacy:** Joan Schiller, Ivy Elkins, Jill Feldman  
**Finding a Mentor:** Chandra Belani, Jonathan Spicer, Narjust Duma

**15:05 - 16:05**      **INDUSTRY SPONSORED SYMPOSIUM: MULTIDISCIPLINARY INSIGHTS ON BIOMARKER TESTING IN METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) PRESENTED BY PFIZER**

---

**16:30 - 17:30**      **HAPPY HOUR  
JOIN OUR FACULTY AND OTHER DELEGATES FOR A RELAXING NETWORKING HOUR.**

---

# Day 5 Saturday, February 26, 2022

**10:00 - 11:40****Session 10: Targeted Therapies - KRAS**

---

Session Chairs: Kathryn Arbour, USA &amp; Everett Vokes, USA

- 10:00 Overview KRAS Science and Signaling**  
*Trever Bivona, USA*
- 10:10 KRAS G12C**  
*Rebecca Heist, USA*
- 10:20 Resistance to KRAS Inhibitors**  
*Mark Awad, USA*
- 10:30 Co-mutations Including Lung Map S1900E**  
*Sukhmani Padda, USA*
- 10:40 RAS Inhibition, G12D Inhibition**  
*Gregory Riely, USA*
- 10:50 Emerging KRAS G12C inhibitor Combinations with Targeted Therapy**  
*David R. Gandara, USA*
- 11:00 Emerging & Promising Combinations with Immunotherapy**  
*Kristen A. Marrone, USA*
- 11:10 Live Panel Discussion**  
*Misako Nagasaka, USA*  
*Neal Ready, USA*  
*Frederick Wilson, USA*  
*Ramaswamy Govindan, USA*  
*Bob Li, USA*  
*Adrian Sacher, Canada*

**11:45 - 13:15****Session 11: SCLC**

---

**Session Chairs: Gregory Kalemkerian, USA & John Minna, USA**

- 11:45 SCLC - Subtypes and Clinical Significance**  
*Charles Rudin, USA*
- 11:55 Immunotherapy in Limited Stage SCLC**  
*Anne Chiang, USA*
- 12:00 Chemoimmunotherapy in ES-SCLC**  
*Ticiana Leal, USA*
- 12:10 Novel Immunotherapy Approaches (AMG 757, Tirogolumab and Vorolanib)**  
*Taofeek Owonikoko, USA*
- 12:20 SCLC: Novel Agents (Lurbinectedin, Liposomal Irinotecan, APG 1252, Ceralesertib)**  
*Jonathan Lehman, USA*
- 12:30 Other Targets of Interest (CDK) "Rock-a-bye stem cells..."**  
*Lauren Byers, USA*
- 12:35 PARP Inhibitors in SCLC**  
*Christine Hann, USA*
- 12:40 Epigenetic Modifier LSD1 as a Therapeutic Target in Small Cell Lung Cancer**  
*Triparna Sen, USA*
- 12:45 Live Panel Discussion**  
*Carl Gay, USA*  
*Dwight Owen, USA*  
*J.T. Poirier, USA*  
*Ignacio Wistuba, USA*  
*Sonam Puri, USA*  
*Thomas Marron, USA*



# Posters

- P01**     **ART1, an Extracellular mono-ADP-ribosyltransferase Promotes Lung Cancer Growth by Triggering Immuneresistance and Is Upregulated in Response to Cellular Stress**  
Sumit Mukherjee, USA
- P02**     **Change in Mean Platelet Volume in Patients with Non-small Cell Lung Cancer Treated with First-Line Pembrolizumab Predict Survival and Risk of Developing Immune Mediated Adverse Events**  
Mingjia Li, USA
- P03**     **Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer**  
Adam Schoenfeld, USA
- P04**     **Investigation of APR-246 in Small Cell Lung Cancer**  
Misty Shields, USA
- P05**     **Activating MET Tyrosine Kinase Domain Mutations Define a Unique Molecular Subtype of Non-small Cell Lung Cancer**  
Federica Pecci, USA
- P06**     **Outcomes to First-Line Pembrolizumab among Elderly Patients with PD-L1-high ( $\geq 50\%$ ) Non-small Cell Lung Cancer**  
Adriana P. C. Barrichello, USA
- P07**     **Pembrolizumab and Weekly Low Dose Carboplatin and Paclitaxel Compared with Pembrolizumab Alone in Patients with NSCLC and Poor PS**  
Safoa Addo, USA
- P08**     **The CANVAX Cohort Study: Immunogenicity and Safety of COVID-19 Vaccines in Patients with Cancer, in the Era of Variants**  
Vivek Naranbhai, USA
- P09**     **High PD-L1 Expression at Diagnosis Is Associated with Worse Progression Free Survival in Patients with ALK-rearranged Non-small Cell Lung Cancer (NSCLC) on First Line ALK Tyrosine Kinase Inhibitor (TKI) Therapy**  
Yunan Nie, USA
- P10**     **EGFR-Mutant NSCLC with De Novo or Acquired Squamous Histology: Molecular Features and other Clinical Outcomes**  
Catherine Meador, USA
- P11**     **Phase II Study of Lorlatinib in Patients with ROS1-Rearranged Lung Cancer with CNS Progression on Crizotinib**  
Jaime Schneider, USA
- P12**     **Clinicopathologic Characteristics of Patients with KRAS G12D-mutated NSCLC**  
Alissa Cooper, USA
- P13**     **Real-World Experience of Lurbinectedin Beyond the Second Line in Small Cell Lung Cancer**  
Aakash Desai, USA

- P14** **Outcome and Clinicopathologic/Molecular Characteristics of NSCLC with Cutaneous, Subcutaneous And/or Muscular Metastases**  
Jessica Boyce, USA
- P15** **Patterns of First- and Second-Line Systemic Therapy Use Among Adults with Advanced Non-Small Cell Lung Cancer in the PROSPR-Lung Consortium**  
Nikki Carroll, USA
- P16** **Accelerating Lung Cancer Diagnosis and Molecular Profiling through Liquid Biopsy**  
Miguel Garcia, Canada
- P17** **Dissecting the Genomic and Tumor Immune Microenvironment Determinants of Recurrence for Surgically-Resected Stage I NSCLC**  
Joao Victor Alessi, USA
- P18** **Genomic Determinants of Brain Metastases in ALK+ Non-Small Cell Lung Cancer**  
Paola Ghanem, USA
- P19** **Histological Transformation and Off Target Alterations are Frequent Mechanisms of Acquired Resistance for Patients with EGFR-mutant Lung Cancer Treated with First-line Osimertinib**  
Noura Choudhury, USA
- P20** **The Impact of Molecular Driver Mutations on Brain Metastasis Risk Depends on Timing of Brain Metastasis Relative to Diagnosis**  
Julie Wu, USA
- P21** **Co-alterations of BRAF with TP53 in BRAF V600E Non-small Cell Lung Carcinoma**  
Jane SY Sui, USA
- P22** **Circulating Tumor DNA Dynamics in Relapsed Small Cell Lung Cancer Are Predictive of Progression-Free and Overall Survival**  
Christopher Cann, USA
- P23** **Clinical Outcomes of Patients with Advanced EGFR-Mutated NSCLC who Received Initial Treatment with Chemotherapy Followed by EGFR TKI**  
Karen Yun, USA
- P24** **PI4K2A is a Therapeutic Vulnerability in Mesenchymal Lung Cancer Cells**  
Xiaochao Tan, USA
- P25** **Using Machine Learning for Multi-Omics Data to Define Vulnerabilities in a Subset of Squamous Cell Lung Cancers**  
Daniel Kottmann, United Kingdom
- P26** **Effect of Osimertinib and Vitamin D on Murine Gut Microbial Community Structure**  
Lei Deng, USA
- P27** **Leveraging Novel Translational Tools to Enhance Response to Trop2-targeting Antibody-Drug Conjugates**  
Ralph Millett, USA

- P28**      **Serum Proteomics Analysis as a Potential Predictive Biomarker for Survival Outcomes and Immune-related Adverse Events (irAE) in Non-Small Cell Lung Cancer (NSCLC) Receiving Immune Checkpoint Inhibitors (ICIs)**  
Leeseul Kim, USA
- P29**      **Rapid Progression of Metastatic NSCLC treated with First Line Osimertinib: An Institutional Case Series**  
Bailey Fitzgerald, USA
- P30**      **RNA Sequencing to Characterize Pathways in EGFR-mutated Non-Small Cell Lung Cancer**  
Nicole Yun, USA
- P31**      **The Challenges of Targeted Therapy and Tumor Lineage Plasticity – A Case Report**  
Joel Rivera, USA
- P32**      **Trial in Progress: Phase II Study of Bevacizumab in Combination with Chemoimmunotherapy Followed by Maintenance Bevacizumab plus Atezolizumab in Patients with Extensive-Stage Small Cell Lung Cancer and Liver Metastases**  
Kamya Sankar, USA
- P33**      **Combining Immunogenic Chemotherapy with anti-PD1 Checkpoint Immunotherapy for the Treatment of Non-small Cell Lung Cancer**  
Diane Tseng, USA
- P34**      **Early Utilization of Next-Generation Sequencing Identifies Pancreatic Mass as Metastatic Tumor Originating from an EGFR|Mutated Lung Adenocarcinoma**  
Luxi Chen, USA